Sparsentan: The First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile
American Nephrology Nurses Association (ANNA) Annual Symposium 2024
April 14 - 17, 2024
FL
American Society of Nephrology (ASN) Kidney Week 2024
October 23 - 27, 2024
CA
Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd
The Role of Endothelin in IgAN
European Renal Association (ERA) Congress 2024
May 23 - 26, 2024
Stockholm
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
Sparsentan in Patients With IgA Nephropathy: A Prespecified Interim Analysis From a Randomised, Double-Blind, Active-Controlled Clinical Trial
Sparsentan. Dual Angiotensin II AT1 Receptor Blocker and Endothelin ETA Receptor Antagonist, Treatment of Focal Segmental Glomerulosclerosis, Treatment of IgA Nephropathy